Letrozole trials for Breast cancer

All Letrozole trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Letrozole for Breast cancer

• A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
  NCT05035836 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
  NCT05766410 · Phase: Phase 2 · Ages: 20 Years and older · Sex: Female · 2 locations
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
  NCT06790693 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 241 locations
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
  NCT07029399 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 709 locations
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 562 locations
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 359 locations
• A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
  NCT07054190 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 34 locations
• A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
  NCT04985266 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
  NCT06348134 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 4 locations
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
  NCT07492641 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
  NCT06075953 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 28 locations
• Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
  NCT07492394 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
  NCT05891093 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 15 locations
• Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
  NCT03011684 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: Female · 1 location
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
  NCT05768139 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 65 locations
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
  NCT06179303 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
  NCT06930859 · Phase: Not specified · Ages: 18 Years to 99 Years · Sex: All (male and female) · 42 locations
• ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
  NCT06998407 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 181 locations
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
  NCT05827081 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 229 locations
• Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
  NCT05638594 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
  NCT06139107 · Phase: Phase 1 · Ages: 60 Years and older · Sex: Female · 4 locations
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
  NCT05467891 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
  NCT06380751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 302 locations
• Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
  NCT04614194 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Study of AVZO-021 in Patients With Advanced Solid Tumors
  NCT05867251 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
  NCT07288359 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
  NCT07604571 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Study of PF-07248144 in Advanced or Metastatic Solid Tumors
  NCT04606446 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 132 locations
• Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
  NCT07391774 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 177 locations
• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
  NCT05900206 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations

Common questions

How many trials study Letrozole for Breast cancer?

35 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.